IP Group shares jump 8% as Pfizer obesity deal drives 13% NAV gain in 2025

NAV per share rose 13% to 110.4p (from 97.7p) at Dec 31, 2025, driven by £128.2m licensing income tied to Pfizer’s Metsera acquisition; IP Group reported a £66.9m profit vs a £207m loss in 2024 and gross cash of £211m. Reclassification as an 'investment entity' triggered a technical covenant breach on a £120m private placement, forcing £119.7m of borrowings to be reclassified to current liabilities (waiver obtained and cash moved to parent). Shares closed 2025 at 58.6p, a ~47% discount to NAV; management completed a £75m buyback (retiring 9% of shares) and targets >£250m of exits by end-2027, while the £128.2m Pfizer valuation remains contingent on PF’3944 reaching Phase 3 success.

Analysis

The governance/accounting shift has structural consequences beyond a one-off covenant waiver: it raises the bar for parent-level liquidity management and turns intra-group cash movements into market-moving events. That creates predictable episodes of forced asset optimization (transfers, short-term refinancing, or accelerated disposals) that can compress or widen the market discount on a discrete timeline rather than as a smooth mean reversion.

Valuation volatility will be dominated by two lumpy drivers over different horizons: binary clinical/royalty outcomes that revalue contingent streams in months-to-years, and the cadence of exits/portfolio realizations that determine actual cash flow conversion in the next 3–18 months. Markets will treat the royalty stream like a high-implied-volatility biotech option until Phase‑3 outcomes are observed or monetized via sale/securitization.

The management signal of accumulating returns and partnering with an external manager is necessary but not sufficient to close the discount — execution risk (timing and price of exits) and capital structure mechanics matter more. A strategic buyer or activist catalyst is the most credible near-term path to rapid gap compression; absent that, expect a multi-quarter grind with episodic repricing around covenant/waiver announcements and trial milestones.

Key tail risks: a negative trial readout or a forced refinancing event will reprice both equity and any reclassified borrowings sharply lower within days-weeks; conversely, a credible sale/monetization of the royalty stream or material, announced multi-year exit timetable is the fastest de-risking catalyst (months). Position sizing should reflect the path-dependent binary on clinical outcomes and the sequencing risk of portfolio exits.

Key Decisions for Investors

• Long IPO.L (IP Group) equity, 12–24 month horizon — build a 2–4% position on conviction that execution on exits/partnering narrows the discount; target 40–60% upside to NAV-convergence scenarios, hard stop at 25% (or immediate trim on evidence of renewed covenant strain).
• Paired hedge: Long IPO.L + buy PFE 12‑month put spread (10%–20% OTM) sized to cover ~30–50% of equity notional — cost-limited protection that monetizes if Pfizer-linked clinical/royalty outcomes disappoint; expected R/R ~3:1 if IPO.L gap reopens on adverse drug news.
• Credit-relative trade: if company 1–2 year bonds trade at a >300bp spread premium to UK investment-grade peers, buy the bonds (or CDS protection sell) sized small (1–2% NAV-equivalent) to capture carry if covenant noise subsides — exit on definitive refinancing or spread tightening to peer levels.